Course Opens
02/10/2025 at 12:00 PM EST
Credits
1
Credit Expires
04/10/2025
Despite advancements in the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and mantle cell lymphoma (MCL), resistance and recurrence occur frequently and mutations might develop during treatment. Given the diverse range of treatment side effects, it is critical that hematology/oncology clinicians know how to select appropriate medications for each patient as well as have insight about optimization of drug sequencing, used alone or in combination, and the issue of intolerance. Clinicians must possess a comprehensive understanding of these challenges and implement specific management of drug-related toxicities using a shared decision-making and multidisciplinary approach.
In this CE Concepts Grand Rounds series, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing treatment for patients with R/R MCL, and prioritization of patient adherence and active engagement through development of multidisciplinary frameworks to oversee and address adverse events. The faculty will also provide insight through case-based discussions.
At the conclusion of this activity, learners will be able to better:
This activity is supported by an independent educational grant from Lilly.
Academic and community hematologists/oncologists, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.00 contact hours (0.1 CEUs) of continuing pharmacy credit (JA0007101-0000-24-018-L01-P).
This activity is designated for 1.00 contact hours.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology
This activity is designated for 1.00 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas:
OCN®
CBCN®
CPHON®
AOCNP*
BMTCN®
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education Credit for learning and change.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Faculty
Dr. Davids reports the following financial relationships:
Consultant: AbbVie Inc.; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene; Bristol Meyers Squibb; Galapagos; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; MEI Pharma, Inc.; Merck & Co., Inc.; Nuvalent; Secura Bio; Takeda Pharmaceutical Company Limited; and TG Therapeutics, Inc.
Research Support:
Ascentage Pharma; MEI Pharma, Inc.; and Novartis
Other financial or material support:
UpToDate – royalties
Planner
Ms. Goodrich reports the following financial relationships:
Advisory Board: AbbVie Inc.; AstraZeneca; BeiGene; Epizyme, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.
The following individuals have no financial relationships to disclose:
Alaa Bawaneh, MD, PhD (Peer Reviewer)
Albert Eubanks, Jr., RN (Peer Reviewer)
Susan Perry (Planning Committee)
David Modrak, PhD (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online
(requires free account activation), and participants can print their certificate or statement of
credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac.
Visit the Creative Educational Concepts Privacy Policy page for complete information about our privacy policy and practices.
Call us at 859-260-1717 • info@ceconcepts.com
GR-069
Call us at 859-260-1717 • info@ceconcepts.com
